Angeion, which develops and markets devices to treat irregular heartbeats, has announced that Philip Smith has resigned as the company's CEO. The decision was a mutual one between Smith and the company's board of directors. Smith became president and CEO of the company effective January 1, 2011 pursuant to a letter agreement that provided for at-will employment. Gregg Lehman will serve as interim CEO, effective immediately. Angeion release